Vaccines and IBD: What the Guidelines Say About Timing Around Biologics and Immunosuppression

Many of the treatments that bring inflammatory bowel disease under control work by calming or dampening part of the immune system. That is exactly what makes them effective, and it is also why vaccines come up so often in IBD care. When the immune system is being held back by steroids, thiopurines, biologics or newer targeted drugs, the body can be more vulnerable to certain infections, and some of those infections are preventable with vaccination.

The practical question for most people is not simply which vaccines, but when. On this point the major guidelines are unusually consistent. Below is a plain-language summary of what they say, and why timing is the thread running through all of it.

Why Vaccines Are Part of IBD Care

European Crohn's and Colitis Organisation (ECCO) guidance on infections in IBD recommends that a person's vaccination status be reviewed and updated, ideally before immunosuppressive treatment is started (ECCO Guidelines on the Prevention, Diagnosis and Management of Infections in IBD, Journal of Crohn's and Colitis, 2021). The same guidance sorts IBD treatments by how strongly they suppress the immune system, because that degree of immunosuppression is what determines whether certain vaccines can be given safely.

In other words, vaccination in IBD is not a one-size-fits-all checklist. It depends on the specific medication, how much it suppresses immunity, and what a person has already been vaccinated against.

The Timing Principle: Before Treatment Where Possible

The single most repeated message across the guidelines is to deal with vaccines early, ideally before immunosuppressive therapy begins. There are two reasons for this.

The first is safety. Some vaccines are made from a weakened but still live form of a virus or bacterium, and these are the ones that raise concerns once the immune system is suppressed.

The second is effectiveness. Vaccines tend to produce a stronger, more reliable immune response when the immune system is working at full capacity, which is more likely before treatment than during it.

This is why the moment of an IBD diagnosis, or the appointment where a new immunosuppressant is being discussed, is often the best opportunity to get vaccination status up to date.

Live Vaccines: Usually Avoided Once Immunosuppression Has Started

Live attenuated vaccines include measles-mumps-rubella (MMR), varicella (chickenpox), yellow fever, oral typhoid and the nasal-spray live influenza vaccine. Guidelines generally treat these as contraindicated for IBD patients who are already on immunosuppressive therapy, because a weakened live organism carries a theoretical risk when the immune system cannot respond normally (Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in IBD, Part 1: Live Vaccines).

Where a live vaccine is genuinely needed, the guidance is to give it before immunosuppression starts, leaving an interval between the vaccine and the first dose of treatment. ECCO, for example, advises a minimum of three weeks between varicella vaccination and the start of immunosuppression. This is one of the clearest reasons the pre-treatment window matters so much.

Inactivated and Recombinant Vaccines: Considered Safe to Give

The reassuring counterpart to the live-vaccine caution is that the large group of inactivated and recombinant vaccines is considered safe to give at any level of immunosuppression. These include the influenza, pneumococcal, hepatitis B, recombinant herpes zoster (shingles), HPV and COVID-19 vaccines (Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in IBD, Part 2: Inactivated Vaccines).

There is one caveat worth understanding. Because these vaccines are given to a partly suppressed immune system, the response they generate can be weaker than it would be in someone not on treatment. They are still recommended, because a somewhat reduced level of protection is far better than none, and in some cases the timing or number of doses is adjusted to account for this.

The shingles vaccine is a good illustration of how the guidance has evolved. The 2025 Advisory Committee on Immunization Practices adult immunization schedule recommends two doses of the recombinant zoster vaccine for immunocompromised adults aged 19 and older, and notes that vaccines for people on immunosuppressive or biologic therapy are best timed in relation to that therapy, such as at least two weeks before it begins (ACIP Recommended Adult Immunization Schedule for Adults Aged 19 Years or Older, United States, 2025, MMWR). The older live shingles vaccine is avoided in immunosuppressed patients; the newer recombinant version is not live, which is why it can be used.

Hepatitis B and a Few Specific Checks

Guidelines also single out hepatitis B for particular attention. ECCO recommends testing a person's hepatitis B status and vaccinating those who are not already immune, because reactivation of hepatitis B is a recognised risk with some IBD therapies. Hepatitis A vaccination is likewise recommended for seronegative patients. These are the kind of checks a care team can build into the work-up before starting treatment.

What This Means in Practice

If you live with IBD, the useful takeaways are simple. Vaccination is a normal, planned part of your care rather than an afterthought. The best time to get it sorted is early, before immunosuppressive treatment starts, especially for any live vaccine. Once you are on treatment, inactivated and recombinant vaccines remain available and recommended, even if their effect is a little reduced.

What none of this replaces is a conversation with the people who know your case. The right list of vaccines, and the right timing, depends on your specific medication, your degree of immunosuppression and your vaccination history. If you are about to start a biologic or another immunosuppressant, the appointment where that decision is made is the natural moment to ask, "what about my vaccines, and is there anything we should do before I start?"